GlassScriptPhysician profile
Richard A Laws
NPI 1487602207
$4,626.47
in general payments reported to CMS, 2019-2025
24 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $234 · 2021: $233 · 2022: $446 · 2023: $711 · 2024: $756 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $617.35 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $487.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $471.83 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $404.64 | 2022-2025 | Ilumya, Winlevi |
| Abbvie INC. | $401.88 | 2019-2025 | |
| Lilly USA, LLC | $310.79 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $302.79 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $245.80 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $244.96 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $242.50 | 2024-2025 | Sotyktu |
| Ucb, INC. | $221.12 | 2023-2025 | Bimzelx, Cimzia |
| Celgene Corporation | $144.25 | 2019 | |
| Leo Pharma INC. | $88.69 | 2019-2024 | Adbry |
| Galderma Laboratories, L.P. | $72.29 | 2025 | Nemluvio |
| Almirall LLC | $72.10 | 2021-2025 | Klisyri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.75 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.59 | 2021-2023 | Jublia, Arazlo, Duobrii |
| Botanix Sb INC | $37.36 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $33.95 | 2019 | |
| Organon LLC | $32.06 | 2023-2025 | Hadlima, Vtama |
| Boston Scientific Corporation | $18.91 | 2023 | Wavewriter Alpha Prime 16 |
| Dermavant Sciences, INC. | $18.13 | 2024 | Vtama |
| Incyte Corporation | $16.88 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Laws listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.